La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Vita Life Sciences Croissance future

Future contrôle des critères 0/6

Nous ne disposons actuellement pas d'une couverture d'analyste suffisante pour prévoir la croissance et les revenus de Vita Life Sciences.

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	28.0%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	None
Dernière mise à jour	n/a

Mises à jour récentes de la croissance future

Recent updates

Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Mar 22

Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06

Mar 14

Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 28

A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)

Dec 20

Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?

Aug 24

If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late

May 14

Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?

Mar 18

Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?

Feb 17

Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?

Jan 20

Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching

Dec 22

Vita Life Sciences Limited's (ASX:VLS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Nov 19

Vita Life Sciences Limited's (ASX:VLS) Prospects Need A Boost To Lift Shares

Jul 14

Dans cette section, nous présentons généralement des projections de croissance du chiffre d'affaires et des bénéfices basées sur les estimations consensuelles d'analystes professionnels afin d'aider les investisseurs à comprendre la capacité de l'entreprise à générer des bénéfices. Mais comme Vita Life Sciences n'a pas fourni suffisamment de données passées et n'a pas de prévisions d'analystes, ses bénéfices futurs ne peuvent pas être calculés de manière fiable en extrapolant les données passées ou en utilisant les prévisions des analystes.

Il s'agit d'une situation assez rare car 97% des entreprises couvertes par SimplyWall St disposent de données financières passées.

Prévisions de croissance des bénéfices et des revenus

ASX:VLS - Estimations futures des analystes et données financières antérieures (AUD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2023	74	9	12	13	N/A
9/30/2023	72	8	10	10	N/A
6/30/2023	69	7	7	7	N/A
3/31/2023	68	7	5	5	N/A
12/31/2022	67	7	3	3	N/A
9/30/2022	65	8	2	2	N/A
6/30/2022	64	8	1	2	N/A
3/31/2022	61	8	4	4	N/A
12/31/2021	57	8	6	6	N/A
9/30/2021	54	8	6	6	N/A
6/30/2021	50	7	7	7	N/A
3/31/2021	48	6	7	7	N/A
12/31/2020	46	6	7	8	N/A
9/30/2020	46	6	7	7	N/A
6/30/2020	45	5	7	7	N/A
3/31/2020	44	4	5	5	N/A
12/31/2019	42	3	2	2	N/A
9/30/2019	42	2	2	2	N/A
6/30/2019	41	2	2	2	N/A
3/31/2019	41	2	3	3	N/A
12/31/2018	41	2	4	4	N/A
9/30/2018	40	3	N/A	N/A	N/A
6/30/2018	40	4	4	5	N/A
3/31/2018	38	3	4	4	N/A
12/31/2017	37	3	3	3	N/A
9/30/2017	37	3	N/A	N/A	N/A
6/30/2017	37	3	N/A	4	N/A
3/31/2017	38	3	N/A	5	N/A
12/31/2016	38	3	N/A	5	N/A
9/30/2016	38	4	N/A	4	N/A
6/30/2016	38	5	N/A	3	N/A
3/31/2016	39	5	N/A	4	N/A
12/31/2015	39	4	N/A	5	N/A
9/30/2015	38	4	N/A	6	N/A
6/30/2015	37	4	N/A	6	N/A
3/31/2015	37	6	N/A	6	N/A
12/31/2014	37	7	N/A	6	N/A
9/30/2014	36	7	N/A	6	N/A
6/30/2014	36	7	N/A	5	N/A
3/31/2014	36	6	N/A	5	N/A
12/31/2013	35	5	N/A	5	N/A
9/30/2013	34	4	N/A	4	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Données insuffisantes pour déterminer si la croissance des bénéfices prévue de VLS est supérieure au taux d'épargne ( 2.4% ).

Bénéfices vs marché: Données insuffisantes pour déterminer si les bénéfices de VLS devraient croître plus rapidement que le marché Australian

Croissance élevée des bénéfices: Données insuffisantes pour déterminer si les bénéfices de VLS devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de VLS devraient croître plus rapidement que le marché Australian.

Croissance élevée des revenus: Données insuffisantes pour déterminer si les revenus de VLS devraient croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de VLS devrait être élevé dans 3 ans

Vita Life Sciences Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Vita Life Sciences Limited Provides Earnings Guidance for the Full Year Ending December 31, 2023

Vita Life Sciences Provides Earnings Guidance for the Full Year Ending 31 December 2022

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2022

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2021

Recent updates

Now 22% undervalued

Non-Executive Chairman recently sold AU$654k worth of stock

New minor risk - Insider selling

MD & Director recently sold AU$1.9m worth of stock

Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Upcoming dividend of AU$0.06 per share

Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06

Vita Life Sciences Limited, Annual General Meeting, May 15, 2024

Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year

Final dividend increased to AU$0.06

Full year 2023 earnings released: EPS: AU$0.17 (vs AU$0.13 in FY 2022)

New minor risk - Insider selling

Vita Life Sciences Limited Provides Earnings Guidance for the Full Year Ending December 31, 2023

Upcoming dividend of AU$0.03 per share at 3.7% yield

First half 2023 earnings released: EPS: AU$0.074 (vs AU$0.069 in 1H 2022)

Vita Life Sciences Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, 6 October 2023

Vita Life Sciences Limited Appoints Peter Osborne as an Independent Non-Executive Director

Investor sentiment improves as stock rises 15%

Upcoming dividend of AU$0.033 per share at 3.9% yield

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

No independent directors

A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)

Vita Life Sciences Provides Earnings Guidance for the Full Year Ending 31 December 2022

No independent directors

Vita Life Sciences Limited Announces Board Changes, Effective 30 September 2022

Upcoming dividend of AU$0.028 per share

Vita Life Sciences Limited Declares Fully Franked Interim Dividend for the Six Months Ended June 30, 2022, Payable on 7 October 2022

First half 2022 earnings released: EPS: AU$0.069 (vs AU$0.07 in 1H 2021)

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2022

Non-Executive Chairman exercised options to buy AU$433k worth of stock.

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Upcoming dividend of AU$0.03 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Vita Life Sciences Limited Announces Dividend for Six Months Ended December 31, 2021, Payable on April 7, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Upcoming dividend of AU$0.028 per share

Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?

First half 2021 earnings released: EPS AU$0.07 (vs AU$0.058 in 1H 2020)

Independent Non-Executive Director Jonathan Tooth has left the company

Investor sentiment improved over the past week

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2021

If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late

Full year 2020 earnings released: EPS AU$0.12 (vs AU$0.057 in FY 2019)

Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?

Investor sentiment improved over the past week

Upcoming Dividend of AU$0.028 Per Share

Full year 2020 earnings released: EPS AU$0.12 (vs AU$0.057 in FY 2019)

Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?

Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?

Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching

New 90-day high: AU$1.00

Vita Life Sciences Limited's (ASX:VLS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Upcoming Dividend of AU$0.015 Per Share

New 90-day high - AU$0.95

First half earnings released

New 90-day high - AU$0.70

Vita Life Sciences Limited's (ASX:VLS) Prospects Need A Boost To Lift Shares

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance